908 Devices (NASDAQ:MASS) vs. Sonova (OTCMKTS:SONVY) Financial Survey

Sonova (OTCMKTS:SONVY) and 908 Devices (NASDAQ:MASS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Sonova and 908 Devices’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonova	N/A	N/A	N/A
908 Devices	34.68%	-14.99%	-11.47%

Risk & Volatility

Sonova has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Sonova and 908 Devices, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonova	1	4	1	2	2.50
908 Devices	1	0	1	0	2.00

908 Devices has a consensus price target of $12.00, indicating a potential upside of 107.61%. Given 908 Devices’ higher possible upside, analysts clearly believe 908 Devices is more favorable than Sonova.

Insider & Institutional Ownership

0.0% of Sonova shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 0.0% of Sonova shares are held by company insiders. Comparatively, 23.7% of 908 Devices shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Sonova and 908 Devices”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonova	$4.36 billion	2.95	$610.01 million	N/A	N/A
908 Devices	$56.20 million	3.84	$19.49 million	$0.55	10.51

Sonova has higher revenue and earnings than 908 Devices.

Summary

Sonova beats 908 Devices on 7 of the 12 factors compared between the two stocks.

About Sonova

Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

About 908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.